Free shipping on all orders over $ 500

Tolebrutinib

Cat. No. M10274
Tolebrutinib Structure
Synonym:

SAR442168; PRN2246

Size Price Availability Quantity
5mg USD 320  USD320 In stock
10mg USD 480  USD480 In stock
50mg USD 1280  USD1280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tolebrutinib (SAR442168) is a potent, selective, orally active and blood-brain barrier capable bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 0.4 and 0.7 nM in Ramos B cells and HMC microglia, respectively. Tolebrutinib has an effect on central nervous system immunity. Tolebrutinib can be used in multiple sclerosis (MS) studies.

Chemical Information
Molecular Weight 455.51
Formula C26H25N5O3
CAS Number 1971920-73-6
Solubility (25°C) DMSO 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] F Piehl. J Intern Med. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis

[2] Philipp von Hundelshausen, et al. Cancers (Basel). Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease

[3] Kenneth Dahl, et al. J Labelled Comp Radiopharm. Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [ 11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation

[4] Daniel S Reich, et al. Lancet Neurol. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

[5] H Yesid Estupin, et al. Front Cell Dev Biol. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects

Related BTK Products
TL-925

TL-925 is a potentially first-in-class Bruton's tyrosine kinase (BTK) inhibitor that targets mast cell-mediated ocular inflammation and hypersensitivity and can be used in studies related to dry eye.

JAK3/BTK-IN-6

JAK3/BTK-IN-6 is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively.

NX-2127

NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

DBt-10

DBt-10 is a potent BTK degrader.

BTK-IN-27

BTK-IN-27 is a BTK inhibitor (IC50: 0.2 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Tolebrutinib, SAR442168; PRN2246 supplier, BTK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.